Merck & Co. Inc. stock (US58933Y1055): steady trading ahead of valuation check on Wall Street

Merck & Co. Inc. shares on the NYSE traded around the 120 USD mark this week as investors weighed the US pharma group’s earnings profile, dividend yield and valuation metrics against broader healthcare peers.

Merck & Co. Inc. shares continued to change hands in a tight range this week, with the New York-listed pharma stock trading around USD 120 per share as investors reassessed the company’s earnings profile and valuation within the US large-cap healthcare space, according to data from Robinhood as of 05/28/2026.

The stock, which is listed on the New York Stock Exchange under the ticker MRK, moved between USD 119.36 and USD 121.48 on 05/28/2026, closing at roughly USD 120.16 and implying a market capitalization close to USD 297 billion, based on Robinhood price information as of 05/28/2026.

For US investors, the home-market perspective remains central, with Merck forming part of the US blue-chip universe and trading in US dollars on the NYSE, where liquidity and institutional ownership are high compared with secondary listings in Europe.

In valuation terms, the stock recently traded on a price-to-earnings ratio in the mid-30s and offered a dividend yield of around 2.8 percent, using Robinhood figures as of 05/28/2026, metrics that many investors use as a starting point when comparing Merck with other large pharmaceutical names in the United States.

Beyond the US, Merck is also accessible to German retail investors through trading venues such as Tradegate and Frankfurt, where the shares are quoted in euros based on the US line, though liquidity and reference pricing continue to be driven by New York.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Rahway, United States
• Core markets: United States, Europe, Asia-Pacific and other global healthcare markets
• Key revenue drivers: Oncology therapies, vaccines, hospital acute care products and animal health solutions
• Home exchange/listing venue: New York Stock Exchange (MRK)
• Trading currency: USD

Merck & Co. Inc.: core business model

Merck & Co. Inc. focuses on developing and commercializing prescription medicines, vaccines and animal health products, with revenue anchored in oncology and vaccines complemented by hospital acute care and animal health franchises.

Valuation metrics and multiples for Merck & Co. Inc.

From a valuation angle, Merck currently trades at levels that reflect both its established product portfolio and the market’s expectations for future growth in key therapeutic areas, using recent market data as a reference point.

According to Robinhood pricing data as of 05/28/2026, Merck’s shares around USD 120.16 were associated with a price-to-earnings ratio of about 33.8, a multiple that places the stock above some slower-growing defensive healthcare names but still within the broader range observed in US large-cap pharmaceuticals.

The same Robinhood dataset as of 05/28/2026 indicates that Merck offered a dividend yield of roughly 2.8 percent at the prevailing share price, giving investors a regular cash return component in addition to any potential capital appreciation tied to the company’s pipeline execution and earnings trajectory.

When considering enterprise value, many market participants also monitor EV-to-EBITDA and similar cash-flow-based metrics, although specific latest-ratio figures for Merck vary across data providers and depend on whether forward or trailing earnings estimates are used.

Alongside these headline indicators, some investors cross-check Merck’s valuation against the wider S&P 500 and the S&P 500 Health Care sector to gauge whether the stock trades at a premium or discount relative to the broader US equity market and its direct industry group.

Conclusion

With Merck & Co. Inc. trading near USD 120 on the NYSE and showing a P/E ratio around the mid-30s along with an indicated dividend yield of about 2.8 percent, the stock remains closely watched by investors assessing risk-reward in US large-cap healthcare.

The current valuation metrics highlight how the market is pricing Merck’s existing portfolio and pipeline prospects, while also offering a reference point for comparison with both the wider S&P 500 and global pharmaceutical peers.

How these numbers evolve around future earnings reports, regulatory milestones and product launches will likely shape investor sentiment toward the shares over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.